Prot# ACF4325g: An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Rituximab in Patients with CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodg